Trazodone: Primary Indication and Clinical Uses
Trazodone is FDA-approved exclusively for the treatment of major depressive disorder (MDD) in adults 1. However, it is extensively used off-label for insomnia and other conditions, though current clinical practice guidelines advise against this practice due to insufficient evidence and significant safety concerns.
FDA-Approved Indication
- Major Depressive Disorder (MDD): Trazodone is indicated as an antidepressant for adults with MDD 1. The medication demonstrates dose-dependent effects, with antidepressant efficacy typically achieved at 150-300 mg daily 2.
Off-Label Uses (Not Recommended by Guidelines)
Insomnia
Current guidelines strongly advise against using trazodone for chronic insomnia disorder 3. The 2019 VA/DoD guidelines explicitly recommend against trazodone for insomnia treatment based on:
- Lack of efficacy: A systematic review found no differences in sleep efficiency or discontinuation rates between trazodone (50-150 mg) and placebo 3
- While trazodone showed some improvement in subjective sleep quality, it failed to improve objective measures including sleep onset latency, total sleep time, or wake after sleep onset 3
- Studies were of very short duration (mean 1.7 weeks) with limited follow-up (1-4 weeks) 3
- The low-quality evidence supporting efficacy was outweighed by its adverse effect profile 3
Older Guidelines' Perspective on Insomnia
Earlier 2008 guidelines 4 noted that trazodone was commonly used off-label for insomnia despite weak evidence. These guidelines stated:
- Evidence for efficacy when used alone is "relatively weak" 4
- Studies of "varying quality and design" suggested only "moderate efficacy" for improving sleep quality/duration 4
- Trazodone is "not FDA approved for insomnia and efficacy for this indication is not well established" 4
- There is "virtually no evidence-based data to support its efficacy" in older adults 5
Nightmares in PTSD
A retrospective study in 74 male veterans showed decreased nightmare frequency (from 3.3 to 1.3 nights/week at mean dose 212 mg/day), but 60% experienced side effects and 19% discontinued due to intolerable adverse effects including priapism, daytime sedation, and more vivid nightmares 6.
Behavioral Symptoms in Dementia
The 2015 circadian rhythm sleep disorders guideline explicitly warns that trazodone is "associated with significant risks, including priapism, orthostatic hypotension, and cardiac arrhythmias" when used in older adults 5. A 2002 guideline on Alzheimer's disease mentions trazodone but provides no specific recommendation for its use 7.
Critical Safety Concerns
All prescribers must be aware of trazodone's significant adverse effect profile:
- Priapism: Medical emergency requiring immediate intervention 5, 6
- Orthostatic hypotension: Particularly dangerous in elderly patients, increasing fall risk 5, 8
- Cardiac arrhythmias: Including QT prolongation 5, 1
- Daytime sedation and dizziness: Common, affecting function 6
- Suicidal ideation: Black box warning for increased suicidal thoughts/actions in children, adolescents, and young adults 1
Dosing for Depression
When used for its FDA-approved indication (MDD):
- Low doses (25-75 mg): Sedative and anxiolytic effects 2
- Therapeutic antidepressant doses (150-300 mg): Full antidepressant effect 2
- Multiple formulations available: immediate-release, extended-release, intravenous, and intramuscular 2
Clinical Bottom Line
Trazodone should be prescribed only for major depressive disorder in adults, its sole FDA-approved indication 1. Despite widespread off-label use for insomnia, the most recent and highest-quality evidence (2019-2020 VA/DoD guidelines) explicitly recommends against this practice due to lack of proven efficacy and concerning adverse effects 3. The risks of priapism, orthostatic hypotension, cardiac arrhythmias, and falls—particularly in elderly patients—substantially outweigh any potential benefits for non-approved indications 5, 3.